Beyond the Cox Hazard Ratio: A Targeted Learning Approach to Survival Analysis in a Cardiovascular Outcome Trial Application-Reference-Cited by-同舟云学术

Beyond the Cox Hazard Ratio: A Targeted Learning Approach to Survival Analysis in a Cardiovascular Outcome Trial Application

Published:2023-04-03 Issue:3 Volume:15 Page:524-539
ISSN:1946-6315
Container-title:Statistics in Biopharmaceutical Research
language:en
Short-container-title:Statistics in Biopharmaceutical Research

Author:

Chen David¹^ORCID,Petersen Maya L.¹^ORCID,Rytgaard Helene Charlotte²,Grøn Randi³,Lange Theis²,Rasmussen Søren³,Pratley Richard E.⁴,Marso Steven P.⁵,Kvist Kajsa³,Buse John⁶,van der Laan Mark J.¹

Affiliation:

1. Division of Biostatistics, UC Berkeley School of Public Health, Berkeley, CA

2. Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark

3. Novo Nordisk A/S, Søborg, Denmark

4. AdventHealth Translational Research Institute, Orlando, FL

5. Midwest Heart and Vascular Institute, HCA Midwest Health, Overland Park, KS

6. Division of Endocrinology and Metabolism, UNC School of Medicine, Chapel Hill, NC

Publisher

Informa UK Limited

Subject

Pharmaceutical Science,Statistics and Probability

Link

https://www.tandfonline.com/doi/pdf/10.1080/19466315.2023.2173644

Reference56 articles.

1. Does Cox analysis of a randomized survival study yield a causal treatment effect?

2. Administration UFaD. (2008), “Guidance for Industry Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes.”

3. Administration UFaD (2018), “Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting Announcement,” October 24–25, 2018.

4. Administration UFaD (2020), “Type 2 Diabetes Mellitus: Evaluating the Safety of New Drugs for Improving Glycemic Control: Guidance for Industry.”

5. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020